BioCentury
ARTICLE | Company News

Boehringer, U.K. groups partner for CF gene therapy

August 10, 2018 6:34 PM UTC

Boehringer Ingelheim GmbH (Ingelheim, Germany) will collaborate with several U.K. universities and companies to develop a gene therapy to treat cystic fibrosis. Partners include Oxford BioMedica plc (LSE:OXB), Imperial Innovations Group plc (London, U.K.) and the U.K. Cystic Fibrosis Gene Therapy Consortium, which is composed of Imperial College London, University of Oxford and University of Edinburgh.

The partners will use a replication-deficient lentiviral vector in an inhaled formulation to introduce a healthy copy of the CF transmembrane conductance regulator (CFTR) gene into lung cells. Boehringer said the method has demonstrated high gene transfer efficiency. ...